LBPH - Longboard Pharmaceuticals, Inc. Stock Price, Fair Value and News

$59.98

Delayed as of 13 Dec 2024, 04:00 pm ET

LBPH Stock Valuation Analysis

Valuation

Max Portfolio %

LBPH Price Action

LBPH RSI Chart

LBPH Stock Valuation Analysis

Valuation

Max Portfolio %

LBPH Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LBPH Fundamentals

LBPH Earnings

LBPH Profitability

LBPH Investor Care

Revenue & Growth

How Longboard Pharmaceuticals, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

CEO	Mr. Kevin R. Lind
WEBSITE	longboardpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	32